Introduction
============

For the past 30 years, lung cancer has been the primary cause of cancer-associated mortality in China ([@b1-etm-0-0-6067]). Specifically, \>80% of all lung cancer cases are non-small cell lung cancer (NSCLC), with adenocarcinoma being the most prevalent NSCLC subtype ([@b2-etm-0-0-6067]). Despite increased understanding of lung adenocarcinoma, the 5-year survival rate remains \<17% ([@b3-etm-0-0-6067]--[@b5-etm-0-0-6067]). It is therefore of great importance to develop novel therapeutic targets and effective treatments to improve the prognoses of patients with adenocarcinoma.

The extracellular signal-regulated kinase (ERK) family is typically considered to been associated with the proliferation, differentiation and migration of cells ([@b6-etm-0-0-6067]). However, a number of studies have reported that activation of the Ras/Raf/ERK pathway may induce apoptosis, autophagy and senescence in tumor cells under certain circumstances ([@b7-etm-0-0-6067],[@b8-etm-0-0-6067]). Several commonly used chemotherapeutic agents, including piperlongumine ([@b9-etm-0-0-6067]), paclitaxel ([@b10-etm-0-0-6067]) and Wentilactone A ([@b11-etm-0-0-6067]), activate the Ras/Raf/ERK pathway to extert an anti-proliferative effect.

Ginseng, the root of *Panax ginseng* C.A. Meyer (Araliaceae), has been used as a traditional herbal medicine in China for centuries ([@b12-etm-0-0-6067]). Ginseng possesses a number of pharmacological activities, including immunomodulatory, anti-mutagenic and anti-aging effects ([@b13-etm-0-0-6067]). Ginsenoside Rh2 (G-Rh2) is one of the primary effective constituents of ginseng and has been reported to induce apoptosis in human lung adenocarcinoma A549 cells and human breast cancer MCF-7 cells ([@b14-etm-0-0-6067],[@b15-etm-0-0-6067]).

In a previous study, a number of dammarane-type derivatives were prepared and their activities were investigated ([@b16-etm-0-0-6067]). Qian *et al* ([@b17-etm-0-0-6067]) at the College of Chemistry of Jilin University designed a novel dammarane-type derivative, namely β-D-Glucopyranoside,(3b,12b,20E)-12,25-dihydroxydammar-20 ([@b22-etm-0-0-6067])-en-3-yl, pseudo-G-Rh2, which possesses a different side chain at C-17 compared with G-Rh. In a previous study by our group, pseudo-G-Rh2 was reported to induce apoptosis in human gastric cancer SGC-7901 cells *in vitro* ([@b18-etm-0-0-6067]). However, whether pseudo-G-Rh2 induces apoptosis in lung adenocarcinoma A549 cells remains unclear. The aim of the present study therefore was to elucidate the antitumor effects of pseudo-G-Rh2 in lung adenocarcinoma cells.

Materials and methods
=====================

### Chemicals

Pseudo-G-Rh2 ([Fig. 1](#f1-etm-0-0-6067){ref-type="fig"}) was provided by Professor Chen (College of Chemistry, Jilin University, Changchun, China). The purity of pseudo-G-Rh2 used in experiments was \>95% as assessed by high-performance liquid chromatography using Agilent 1100 with a Zoebax Extent C18 column (250×4.6 mm, 5 µm) (both, Agilent Technologies, Inc., Santa Clara, CA, USA) at 25°C. Methanol and water (90:10) was used as the mobile phase, the flow rate was 1.2 ml/min and the sample quantity was 10 µl). Antibodies against procaspase-3 (cat. no. 19677-1-AP), procaspase-9 (cat. no. 66169-1-Ig) and β-actin (cat. no. 20536-1-AP) were purchased from Wuhan Sanying Biotechnology (Wuhan, China). Antibodies against PARP (cat. no. 9542), Bcl-2 (cat. no. 2876), Bax (cat. no. 2772), Ras (cat. no. 3965), phosphorylated (p)-Raf (cat. no. 9427), Raf (cat. no. 9422), p53 (cat. no. 9282), ERK (cat. no. 4695), c-Jun N-terminal kinase (JNK) (cat. no. 9258), p38 (cat. no. 8690), p-ERK (cat. no. 4370), p-JNK (cat. no. 4668) and p-p38 (cat. no. 4511) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The BCA protein assay reagent kit, DAPI staining kit, reactive oxygen species (ROS) assay kit (cat. no. S0033) and Rhodamine 123 were purchased from Beyotime Institute of Biotechnology (Jiangsu, China). An Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit was obtained from Tianjin Sungene Biotech Co., Ltd. (Tianjin, China). MTT and all other reagents were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

### Cell culture and treatment

Lung adenocarcinoma A549 cells were obtained from the Shanghai Institute of Cell Biology, Chinese Academic of Sciences (Shanghai, China). A549 cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Zhejiang Tianhang Biotechnology Co., Ltd., Huzhou, China) under standard culture conditions (37°C in an atmosphere containing 5% CO~2~). Culture medium was replaced every 3 days with fresh complete medium and maintained in log phase growth. Pseudo-G-Rh2 was dissolved in dimethyl sulfoxide (DMSO) at room temperature and 104 µM was the maximum solubility. Then Pseudo-G-Rh2 was added to the culture media at the final concentrations. The final concentration of DMSO was \<0.1%. Cells were treated with different concentrations of Pseudo-G-Rh2 (40, 56, 72, 88 or 104 µM) for 24, 48 and 72 h at 37°C, prior to an MTT assay. The cells were administered with 24, 48 or 96 µM Pseudo-G-Rh2 for 24 h at 37°C prior to DAPI staining, flow cytometry and western blot analysis.

### MTT assay

Cell viability was assessed using an MTT assay as previously described ([@b19-etm-0-0-6067]). Briefly, A549 cells were seeded into 96-well plates (5×10^4^/ml) following treatment with 40, 56, 72, 88 or 104 µM pseudo-G-Rh2. Cells were incubated for 20 h at 37°C. A total of 10 µl of MTT solution (5 mg/ml in PBS) was added to each well and plates were incubated for a further 4 h at 37°C. A total of 100 µl DMSO was added to each well and plates were agitated for 10 min. Absorbance was measured at 570 nm using a microplate reader (SpectraMax 340PC384; Molecular Devices LLC, Sunnyvale, CA, USA). Cell viability was calculated as a fraction of the untreated cells. The half-maximal inhibitory concentration (IC50) was calculated using GraphPad Prism v5 (GraphPad Software, Inc., La Jolla, CA, USA).

### DAPI staining

DAPI staining was performed as previously described ([@b20-etm-0-0-6067]). Briefly, A549 cells were seeded on 6-well plates (9×10^4^/ml) and treated with 24, 48 and 96 µM pseudo-G-Rh2 at 37°C for 24 h. Cells were collected and washed twice with PBS, permeabilized with 0.1% Triton X-100 and stained with 2 µg/ml DAPI for 10 min at room temperature. Cells were subsequently observed using a fluorescence microscope (magnification, ×100; Nikon TE-2000U; Nikon Corporation, Tokyo, Japan).

### Annexin V-FITC/propidium iodide (PI) assay

To assess pseudo-G-Rh2-induced apoptosis in A549 cells, Annexin V-FITC/PI staining and flow cytometry were performed as previously described with an ([@b19-etm-0-0-6067]). Briefly, following pseudo-G-Rh2 treatment, A549 cells were collected, washed twice with PBS and resuspended in 300 µl of binding buffer containing PI and Annexin V-FITC. The samples were incubated for 15 min at room temperature in dark and subsequently detected by flow cytometry and CellQuest™ Pro (version 6.0) software (BD Biosciences, Franklin Lakes, NJ, USA).

### Caspase activity assay

The activities of caspase-3 and caspase-9 were measured using a caspase 3 Activity Assay kit (cat. no. C1115) and caspase 9 Activity Assay kit (cat. no. C1157) according to the manufacturer\'s protocol (both Beyotime Institute of Biotechnology). Briefly, cell lysates were incubated in a radioimmunoprecipitation lysis buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) for 15 min on ice and centrifuged at 18,000 × g for 10 min at 4°C. Supernatants were collected and total protein was quantified using the Bradford method. Protein lysates was mixed with reaction buffer (Ac-DEVD-pNA for caspase-3, Ac-LEHD-pNA for caspase-9) and incubated at 37°C for 2 h in the dark. Cell absorbance was subsequently measured at 405 nm using a microplate reader. Results were reported as the percentage activity change compared with the control.

### Mitochondrial membrane potential (ΔΨm)

The *ΔΨm* was measured using the cationic dye Rhodamine 123 (cat. no. C2007; Beyotime Institute of Biotechnology) as previously described ([@b21-etm-0-0-6067]). Briefly, A549 cells were treated with 24, 48 and 96 µM pseudo-G-Rh2 for 24 h and incubated with Rhodamine 123 at 37°C for 30 min. Fluorescence intensities were analyzed by flow cytometry and CellQuest™ Pro software as above.

### Measurement of ROS

ROS levels were assessed using the nonfluorescent probe 2′,7′-dichlorofluorescein diacetate (DCFH-DA; Beyotime Institute of Biotechnology) as previously described ([@b22-etm-0-0-6067]). DCFH-DA permeates into cells and is deacetylated by nonspecific esterase in the cell to form 2′,7′-dichlorofluorescein, which is nonfluorescent. The cellular oxidizing agent oxidize DCFH to dichlorofluorescein, which is a highly fluorescent compound ([@b23-etm-0-0-6067]). As such, the amount of ROS produced in the cells is detected by measuring the fluorescence intensity. Following pseudo-G-Rh2 treatment, A549 cells were collected, washed twice with PBS and incubated with 10 µM DCFH-DA at 37°C for 20 min in the dark. Cells were subsequently washed three times with PBS. Fluorescence was observed under a Nikon TE-2000U fluorescence microscope (magnification, ×100) and measured using flow cytometry as above.

### Western blotting

Western blotting was performed to assess protein expression. Following treatment with pseudo-G-Rh2, A549 cells were harvested and lysed in radioimmunoprecipitation assay buffer (Beyotime Biotechnology, Jiangsu, China) for 30 min on ice. The protein concentration was determined using a BCA protein assay kit according to the manufacturer\'s protocol. Proteins (20 µl) were separated by 12% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane, which was subsequently blocked with 5% (w/v) non-fat milk for 1 h at room temperature. Membranes were incubated with the appropriate primary antibodies against procaspase-3, procaspase-9, PARP, Bcl-2, Bax, Ras, p-Raf, Raf, p53, ERK, c-JNK, p38, p-ERK, p-JNK, p-p38 and β-actin at 1:1,000 dilution at 4°C overnight. Primary antibody binding was detected by incubation with a secondary antibody conjugated to horseradish peroxidase. The goat-anti-mouse (cat. no. IH-0031) and goat-anti-rabbit (cat. no. IH-0011) secondary antibodies (Beijing Dingguo Changsheng Biotechnology Co., Ltd., Beijing, China) were used at 1:5,000 dilution at room temperature for 1 h. The bands were visualized using a BeyoECL Plus enhanced chemiluminescence kit (Beyotime Institute of Biotechnology). ImageJ software (version 1.5.0.26; National Institutes of Health, Bethesda, MD, USA) was used for analysis.

### Statistical analysis

The results are expressed as the mean + standard deviation of three independent experiments. Statistical differences were evaluated using one-way analysis of variance with Tukey\'s post hoc test. P\<0.05 was considered to indicated a statistically significant difference.

Results
=======

### Pseudo-G-Rh2 inhibits A549 cell proliferation

To evaluate the antiproliferative effects of pseudo-G-Rh2 *in vitro*, A549 cells were treated with 40, 56, 72, 88 or 140 µM pseudo-G-Rh2 for 24, 48 or 72 h, following which cell viability was assessed by MTT assay. The highest dose of pseudo-G-Rh2 selected was 104 µM, as this is the maximum solubility of this compound in DMSO. The results demonstrated that pseudo-G-Rh2 significantly decreased the viability of A549 cells in a concentration-dependent manner compared with the control ([Fig. 2](#f2-etm-0-0-6067){ref-type="fig"}). The IC50 value was 74.5 µM for 24 h. Based on these results, dosages of 24, 48 and 96 µM pseudo-G-Rh2 were selected for further experiments

### Pseudo-G-Rh2 induces mitochondria-associated apoptosis in A549 cells

To elucidate whether pseudo-G-Rh2 induces apoptosis, DAPI staining was performed. DAPI staining revealed an increase in the number of apoptotic bodies containing nuclear fragmentations in cells treated with pseudo-G-Rh2 compared with the control group ([Fig. 3A and B](#f3-etm-0-0-6067){ref-type="fig"}), which indicates that pseudo-G-Rh2 induces apoptosis in A549 cells. The apoptotic rate was measured using Annexin V-FITC/PI staining and the percentage of apoptotic cells was revealed to be 2.65, 4.44, 14.1 and 48.56% in A549 cells treated with 0, 24, 48 and 96 µM of pseudo-G-Rh2, respectively ([Fig. 3C and D](#f3-etm-0-0-6067){ref-type="fig"}). To further investigate the mechanism by which pseudo-G-Rh2 induces apoptosis in A549 cells, the *ΔΨm* was examined using Rhodamine 123 ([Fig. 4A](#f4-etm-0-0-6067){ref-type="fig"}). The *ΔΨm* (percentage of strong fluorescent cells) in A549 cells treated with 0, 15, 30 and 60 µg/ml pseudo-G-Rh2 for 24 h was 91.35, 88.85, 87.18 and 74.28%, respectively ([Fig. 4A and B](#f4-etm-0-0-6067){ref-type="fig"}). In addition, western blotting revealed that the expression of B-cell lymphoma 2 (Bcl-2) was decreased compared with the control, whereas that of Bcl-2-associated X protein (Bax) was increased ([Fig. 4C-E](#f4-etm-0-0-6067){ref-type="fig"}). Western blotting revealed that precursors of caspase-9 and caspase-3 were decreased in A549 cells following treatment with pseudo-G-Rh2 treatment compared with the control ([Fig. 5A-D](#f5-etm-0-0-6067){ref-type="fig"}). Upregulated cleaved poly ADP-ribose polymerase (PARP), a product of caspase-3, was observed following pseudo-G-Rh2 treatment compared with the control. Furthermore, spectrophotometry results revealed that pseudo-G-Rh2 enhanced the activity of caspase-9 and caspase-3 compared with the control ([Fig. 5E](#f5-etm-0-0-6067){ref-type="fig"}). These results suggest that pseudo-G-Rh2 induces apoptosis via the mitochondrial pathway in A549 cells.

### Pseudo-G-Rh2 increases ROS production

It has previously been reported that ROS serve important roles in mediating cancer initiation, promotion and apoptosis ([@b24-etm-0-0-6067],[@b25-etm-0-0-6067]). To determine whether pseudo-G-Rh2 affects ROS production, A549 cells were treated with 24, 48 or 96 µM pseudo-G-Rh2 for 24 h and subjected to DCFH-DA fluorescence analysis. Pseudo-G-Rh2 increased the intensity of green fluorescence, which indicates ROS-positive cells, in a dose dependent manner compared with the control ([Fig. 6A](#f6-etm-0-0-6067){ref-type="fig"}). The results of flow cytometry revealed that ROS expression (percentage of strong fluorescent cells) was 5.84, 7.86, 11.61 and 35.68% in cells treated with 0, 24, 48 or 96 µM pseudo-G-Rh2 for 24 h, respectively ([Fig. 6B](#f6-etm-0-0-6067){ref-type="fig"}). These results indicate that pseudo-G-Rh2 induces ROS production in A549 cells, which may lead to apoptosis.

### Pseudo-G-Rh2 induces apoptosis via the Ras/Raf/ERK/p53 pathway

ROS is known to be a mediator of mitogen-activated protein kinases (MAPKs) and a number of studies have demonstrated that ROS is able to maintain the activation of Ras, Raf and ERK, resulting in apoptosis and autophagy ([@b9-etm-0-0-6067],[@b26-etm-0-0-6067],[@b27-etm-0-0-6067]). In the present study, the expression of Ras, p-Raf and Raf proteins were assessed using western blotting ([Fig. 7A](#f7-etm-0-0-6067){ref-type="fig"}). Pseudo-G-Rh2 increased the expression of p-Raf ([Fig. 7B](#f7-etm-0-0-6067){ref-type="fig"}), Ras ([Fig. 7C](#f7-etm-0-0-6067){ref-type="fig"}) and p53 ([Fig. 7D](#f7-etm-0-0-6067){ref-type="fig"}) compared with the control in a dose-dependent manner; meanwhile, the ratio of p-Raf and p-ERK was significantly increased. The expression of MAPK family proteins was also assessed ([Fig. 7E](#f7-etm-0-0-6067){ref-type="fig"}) and the results demonstrated that p-ERK ([Fig. 7F](#f7-etm-0-0-6067){ref-type="fig"}) was upregulated by pseudo-G-Rh2 in a dose-dependent manner compared with the control. However, pseudo-G-Rh2 had no significant effect on the ratio of p-p38/p38 or p-JNK/JNK. Increased activation of the Ras/Raf/ERK pathway signaling is able to enhance the stability and activity of tumor suppressor p53, which is known to serve an important role in mediating apoptosis ([@b11-etm-0-0-6067],[@b28-etm-0-0-6067]).

Discussion
==========

Pseudo-G-Rh2, a novel derivative of G-Rh2, has previously been demonstrated to have antitumor activity in human gastric cancer SGC-7901 cells ([@b18-etm-0-0-6067]). In the present study, it was revealed that pseudo-G-Rh2 significantly suppresses cell growth and induces apoptosis in A549 cells *in vitro*. MTT results demonstrated that pseudo-G-Rh2 is cytotoxic in A549 cells, with an IC50 of 74.5 µM. The IC50 obtained in the present study is lower than that reported for SGC-7901 human gastric cancer cells, suggesting that A549 cells are more sensitive to pseudo-G-Rh2 compared with SGC-7901 cells ([@b18-etm-0-0-6067]). DAPI staining revealed an increase in apoptotic bodies containing nuclear fragments following treatment with pseudo-G-Rh2. An Annexin V-FITC/PI double-staining assay further verified the results of DAPI staining, as the apoptosis percentage increased. Together, these results indicate that pseudo-G-Rh2 exerts its anticancer activity via inducing apoptosis.

Apoptosis comprises a series of complicated and sequential cascade reactions ([@b29-etm-0-0-6067]). Apoptosis occurs via three pathways: The cell death receptor-mediated extrinsic pathway, the endoplasmic reticulum stress signaling pathway and the mitochondria-mediated intrinsic pathway ([@b30-etm-0-0-6067]). In the present study, a *ΔΨm* assay revealed that treatment with pseudo-G-Rh2 decreased the *ΔΨm* of A549 cells compared with the control. The loss of *ΔΨm* may result in an increase in mitochondrial cytochrome C release, which in turn promotes activation of the caspase-9 precursor, ultimately leading to apoptosis. Western blotting results revealed that pseudo-G-Rh2 downregulates Bcl-2, procaspase-9 and procaspase-3, whereas Bax and cleaved PARP were upregulated. These results indicate that pseudo-G-Rh2 induces apoptosis in A549 cells via the mitochondrial mediated intrinsic pathway.

The exact mechanisms of pseudo-G-Rh2 are not fully understood. It has been reported that the p38, JNK and ERK pathways, which are the primary pathways of the MAPK family, serve important roles in the proliferation, invasiveness, angiogenesis and cell cycle regulation of a number of cancers, including lung cancer ([@b31-etm-0-0-6067],[@b32-etm-0-0-6067]). The p38 and JNK pathways are typically associated with cell death and the inhibition of cell proliferation, whereas ERK is associated with cell proliferation ([@b33-etm-0-0-6067]). However, a number of studies have reported that the ERK pathway may function as tumor suppressor ([@b9-etm-0-0-6067],[@b11-etm-0-0-6067],[@b34-etm-0-0-6067],[@b35-etm-0-0-6067]). Lv *et al* ([@b11-etm-0-0-6067]) revealed that Wentilactone A induces apoptosis and G2/M arrest of human lung carcinoma cells via excessive activation of the Ras/Raf/ERK/p53-p21 pathway. Furthermore, Randhawa *et al* ([@b9-etm-0-0-6067]) reported that the activation of ERK signaling serves a role in the induction of colon cancer apoptosis by piperlongumine. These inconsistencies may be due to variations in the strength of the cascade signal and external stimuli, including ROS ([@b8-etm-0-0-6067]). During early-stage tumor development, ROS affects gene expression and genome stability, resulting in loss-of-function mutations in p53 ([@b36-etm-0-0-6067]). Furthermore, ROS induces metabolic adaptations ([@b37-etm-0-0-6067]), which are crucial for the pathogenesis of cancer. However, during the later stages of cancer, ROS accumulation induces p53 expression, which in turn causes cell cycle arrest at the G2/M phase, DNA fragmentation and apoptosis ([@b38-etm-0-0-6067]). It has been reported that G may induce cell cycle arrest or cell death by increasing ROS release in cancer cells ([@b39-etm-0-0-6067],[@b40-etm-0-0-6067]). ROS has also been reported to be a mediator of ERK-induced cell death ([@b41-etm-0-0-6067],[@b42-etm-0-0-6067]); specifically, elevated ROS results in sustained ERK activity, which in turn causes enhanced p53 expression ([@b43-etm-0-0-6067]). p53 protein is associated with Bcl-2 family regulation and is believed to serve a critical role in mediating apoptosis ([@b43-etm-0-0-6067],[@b44-etm-0-0-6067]). ERK activity has been reported to directly affect mitochondrial function by decreasing mitochondrial respiration and *ΔΨm*, which may lead to mitochondrial membrane disruption and cytochrome c release ([@b45-etm-0-0-6067],[@b46-etm-0-0-6067]). In addition, Ras/Raf/ERK activity has been reported to be associated with the upregulation of proapoptotic members of the Bcl-2 family, including Bax and p53 upregulated modulator of apoptosis, as well as the downregulation of Bcl-2 and Bcl-extra large ([@b44-etm-0-0-6067],[@b47-etm-0-0-6067],[@b48-etm-0-0-6067]).

In the present study, the effect of pseudo-G-Rh2 on the Ras/Raf/ERK pathway was assessed by measuring the expression of total Ras/Raf/ERK and p-Ras/Raf/ERK family members. The results demonstrated that pseudo-G-Rh2 significantly increased the ratio of p-Raf and p-ERK in A549 cells *in vitro*, whereas no significant changes were observed in the ratio of p-p38/p38 and p-JNK/JNK. These results suggest that pseudo-G-Rh2 induces apoptosis in A549 cells via the Ras/Raf/ERK pathway, which was further confirmed by the increase in ROS levels and upregulation of p53.

In conclusion, the results of the present study demonstrated that pseudo-G-Rh2 induced apoptosis in lung adenocarcinoma A549 cells via the mitochondrial mediated intrinsic pathway. During this process, pseudo-G-Rh2 increased ROS generation and caused the subsequent activation of the Ras/Raf/ERK/p53 signaling pathway. These results provide an insight into the mechanism of pseudo-G-Rh2-induced adenocarcinoma cell apoptosis, suggesting that pseudo-G-Rh2 may have potential as a chemotherapeutic agent for the treatment of lung adenocarcinoma. However, the present study is with limitations. It was confirmed that the activation of the Ras/Raf/ERK/p53 signaling pathway was involved in the apoptosis induced by pseudo-G-Rh2, however whether the Ras/Raf/ERK/p53 signaling pathway is the only target of pseudo-G-Rh2 remains unclear. Further investigation is required to confirm the mechanisms of pseudo-G-Rh2 by employing specific inhibitors of the Ras-ERK signaling pathway. In addition, the authors intend to utilize multi time point treatments of pseudo-G-Rh2 and other lung cancer cell lines in the future to confirm the effect of pseudo-G-Rh2 in NSCLC.
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![The chemical structures of (A) G-Rh2 and (B) pseudo-G-Rh2. G, ginsenoside.](etm-15-06-4916-g00){#f1-etm-0-0-6067}

![Effects of pseudo-G-Rh2 on the viability of A549 cells. An MTT assay was performed to assess cell viability following treatment with 0, 40, 56, 72 and 88 µM pseudo-G-Rh2 for 24, 48 or 72 h. \*P\<0.05 vs. control. G, ginsenoside.](etm-15-06-4916-g01){#f2-etm-0-0-6067}

![Effect of pseudo-G-Rh2 on apoptosis. (A) Representative photomicrographs and (B) quantified results of DAPI staining in the control and 24, 48 and 96 µM pseudo-G-Rh2 treatment groups. A549 cells were stained with Annexin V-FITC/PI, (C) analyzed by flow cytometry and (D) quantified. Scale bar=50 µm. \*P\<0.05 vs. control. G, ginsenoside; FITC, fluorescein isothiocyanate; PI, propidium iodide.](etm-15-06-4916-g02){#f3-etm-0-0-6067}

![Effect of Pseudo-G-Rh2 on mitochondrial pathways. A549 cells were incubated with 24, 48 or 96 µM pseudo-G-Rh2 for 24 h and Rhodamine 123 dye for 30 min. Fluorescence emission was (A) measured using flow cytometry and (B) quantified. (C) Western blotting was performed and the expression of (D) Bax and (E) Bcl-2 was quantified. \*P\<0.05 vs. control. G, ginsenoside; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein.](etm-15-06-4916-g03){#f4-etm-0-0-6067}

![Effects of pseudo-G-Rh2 on caspase activity in A549 cells. A549 cells were incubated with 24, 48 or 96 µM pseudo-G-Rh2 for 24 h. (A) The expression of caspases-9, caspase-3 and PARP was determined using western blotting. (B) Caspase-9 and caspase-3 activities were assessed using Ac-LEHD-pNA and Ac-DEVD-pNA, respectively. Western blotting results for (C) procaspase-3, (D) procaspase-9 and (E) cleaved PARP were quantified. \*P\<0.05 vs. control. G, ginsenoside; PARP, poly ADP-ribose polymerase.](etm-15-06-4916-g04){#f5-etm-0-0-6067}

![Effect of pseudo-G-Rh2 on ROS. A549 cells were treated with 24, 48 or 96 µM pseudo-G-Rh2 for 24 h. The culture medium was removed and each well was treated with DCF-diacetate solution for 30 min. (A) Fluorescence was observed under an inverted microscope and measured using (B) flow cytometry to assess ROS production. Cells containing a higher amount of ROS emitted hyperfluorescence. (C) Flow cytometry results were subsequently quantified. Scale bar=50 µm \*P\<0.05, vs. control. G, ginsenoside; ROS, reactive oxygen species; DCF, 2′,7′-dichlorofluorescein.](etm-15-06-4916-g05){#f6-etm-0-0-6067}

![Effect of pseudo-G-Rh2 on the Ras/Raf, p53 and MAPK pathway. (A) A549 cells were incubated with 24, 48 or 96 µM pseudo-G-Rh2 for 24 h and assessed using western blotting. The expression of (B) p-Raf, (C) Ras and (D) p53 was quantified. (E) Western blotting was also performed to assess the expression of MAPK members (F) p-ERK, (G) p-p38 and (H) p-JNK. \*P\<0.05 vs. control. G, ginsenoside; MAPK, mitogen activated protein kinase; p, phosphorylated; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase.](etm-15-06-4916-g06){#f7-etm-0-0-6067}
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